The abstract is read at the publisher; the summary is JClub's.
In a dynamic in vitro bladder infection model with ESBL-producing Escherichia coli, standard-dose oral amoxicillin-clavulanic acid (500/125 mg, 8-hourly) achieved end-of-treatment clearance in 14/16 isolates, with %T>MIC predicting outcomes (R2=0.9062).
- Why it matters: Acquired ESBL genes can restrict effective oral options for UTIs, yet urine-specific exposure targets for bacterial clearance are not well quantified.
- What they did: Sixteen isolates (12 clinical ceftriaxone-resistant uropathogens, 4 laboratory) were simulated with oral dosing producing Cmax 935 mg/L and AUC0-24 14272 mg/L, then exposure-response and PK/PD predictors were assessed using %T>MIC.
- The result: Monte Carlo simulations showed standard-dose 8-hourly met all %T>MIC targets in >95% of virtual patients for MICs ?64 mg/L (CLSI or EUCAST), supporting clinical breakpoints for uncomplicated UTI at MIC ?64 mg/L.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.